U.S. Markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.62-0.59 (-1.78%)
At close: 4:00PM EDT

32.49 -0.13 (-0.39%)
After hours: 4:11PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close33.21
Open32.95
Bid30.10 x 1400
Ask33.98 x 1200
Day's Range31.73 - 33.05
52 Week Range12.59 - 38.52
Volume377,133
Avg. Volume1,021,473
Market Cap2.824B
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.81
  • GlobeNewswire

    Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference

    SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020, at 11:30 a.m. EST. A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

  • GlobeNewswire

    Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

    SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 5:30 p.m. ET to report its second quarter 2020 financial results and provide a corporate update. In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 8295527. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

  • Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.